Organization (Industry)
PFIZER INC.
ClinicalTrials.gov lists PFIZER INC. as lead sponsor of 3,465 trials, counting the companies grouped under it. PFIZER INC. itself has 1,913 active development programs and 510 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 115 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 140 in 2026 and about 140 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (100 to 500), forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 4 trials are registered to start in 2027 or later.
Logo Pfizer, Team, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers PFIZER INC. and 24 companies grouped under it: 3,465 lead-sponsored trials (3,315 its own, 150 in the grouped companies) and 63 legal-entity registrations (34 its own, 29 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (24)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| SEAGEN B.V. | 88 | 4 |
| Javelin Pharmaceuticals | 14 | 0 |
| Medivation, Inc. (United States) | 14 | 1 |
| PHARMACIA & UPJOHN COMPANY LLC | 11 | 1 |
| Global Blood Therapeutics (United States) | 9 | 1 |
Showing 5 of 24 member companies.
Disease areas (828)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 336 |
| Lung Neoplasms | 221 |
| Diabetes Mellitus | 195 |
| Arthritis, Rheumatoid | 185 |
| Carcinoma, Non-Small-Cell Lung | 180 |
Showing 5 of 828 disease areas.
Trials by start year as sponsor or collaborator (35)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 115 |
| 2025 | 144 |
| 2024 | 133 |
| 2023 | 168 |
| 2022 | 183 |
| 2021 | 193 |
| 2020 | 192 |
| 2019 | 181 |
| 2018 | 164 |
| 2017 | 149 |
Showing 10 of 35 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 114 trials still running at the 2026-10-09 snapshot; registered median of 14 months across 2,671 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1,913)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Abrocitinib | Dermatitis, Atopic | Phase 3 | 12 |
| 20 Valent Pneumococcal Conjugate Vaccine (20vPnC) | Pneumococcal Infections | Phase 3 | 16 |
| 20 Valent Pneumococcal Conjugate Vaccine (20vPnC) | Streptococcal Infections | Phase 3 | 16 |
| FULVESTRANT | Breast Neoplasms | Phase 3 | 11 |
| Etrasimod | Inflammatory Bowel Diseases | Phase 3 | 11 |
Showing 5 of 1,913 active programs.
Approved assets (510)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| (CP-6890,550) Tofacitinib | 72 |
| SUNITINIB | 50 |
| ETANERCEPT | 48 |
| Varenicline | 39 |
| Crizotinib | 38 |
Showing 5 of 510 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 56% hit target (n=881) | 44% on time (n=840) |
Journals published in (1,147)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 213 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 165 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 69 |
| Lancet (London, England) | 68 |
| Circulation | 67 |
Showing 5 of 1,147 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 7,775 | 281 | 2025-12-16 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 62,579,000,000 | 7,771,000,000 | 10,437,000,000 |
| 2024 | 63,627,000,000 | 8,031,000,000 | 10,822,000,000 |
| 2023 | 59,553,000,000 | 2,119,000,000 | 10,679,000,000 |
| 2022 | 101,175,000,000 | 31,372,000,000 | 11,428,000,000 |
| 2021 | 73,636,000,000 | 21,979,000,000 | 10,360,000,000 |
| 2020 | 41,651,000,000 | 9,159,000,000 | 8,709,000,000 |
| 2019 | 40,905,000,000 | 16,026,000,000 | 8,385,000,000 |
| 2018 | 40,825,000,000 | 11,153,000,000 | 7,760,000,000 |
| 2017 | 52,546,000,000 | 21,308,000,000 | 7,683,000,000 |
| 2016 | 52,824,000,000 | 7,215,000,000 | 7,892,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (65)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-04 | ATM offering | not disclosed | Sec extracted |
| 2026-05-04 | ATM offering | not disclosed | Sec extracted |
| 2026-01-06 | ATM offering | 125,000,000 | Sec extracted |
| 2025-11-21 | Debt financing | 6,000,000,000 | Sec extracted |
| 2025-11-20 | Debt financing | 5,990,635,000 | Edgar offerings |
Showing 5 of 65 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 49 |
FDA recalls (125)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Vial Label: Epinephrine Injection, USP, 1mg/10mL (0.1 mg/mL), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045, USA. NDC 0409-4933-05. Case: NDC 0409-4933-10. | Class II | 2025-08-04 |
| Vial Label: 8.4% Sodium Bicarbonate Injection, USP, 50mEq/50 mL (1 mEq/mL), Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-6637-24. Case NDC: 00409-6637-14. | Class II | 2025-08-04 |
| Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-count bottle, Rx only, Distributed by: Pfizer Inc., New York, NY 10017, Made in Austria, NDC 60793-851-01. | Class II | 2025-07-29 |
| Bicillin L-A (penicllin G benzathine injectable suspension), 1,200,000 units per 2 mL, 2 mL-vial, Rx Only, Distributed by Pfizer Inc., New York, NY 10001. Made in Austria, Carton NDC - 60793-701-10, Syringe NDC - 60793-701-02 | Class II | 2025-07-10 |
| Bicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units per 4 mL, 4ml-vial, Rx Only, Distributed by Pfizer Inc., New York, NY 10001, Made in Austria, Carton NDC- 60793-702-10 , Syringe NDC-60793-702-04 | Class II | 2025-07-10 |
Showing 5 of 125 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 108 | 2026-05-26 |
Manufacturing and distribution sites (6)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Pfizer Inc | Parsippany, US | FDA, Health Canada | |
| Pfizer Inc | Chesterfield, US | EMA, FDA, Health Canada | |
| Pfizer Pharmaceuticals, LLC | Barceloneta, US | Health Canada | |
| Pfizer Inc. | Sanford, US | Health Canada | |
| Pfizer Inc. | Rouses Point, US | Health Canada |
Showing 5 of 6 sites.
Organization relationships (704)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 50 |
| GSK plc | Co sponsors trial with | 34 |
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 26 |
| Mass General Brigham | Co sponsors trial with | 22 |
| University of California System | Co sponsors trial with | 20 |
Showing 5 of 704 relationships.
Latest dated events (14,669)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-05-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 14,669 events.
CLIA clinical laboratory certificates (10)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| PFIZER, INC | Certificate of waiver | Active |
| PFIZER INC | Certificate of waiver | Active |
| PFIZER | Certificate of waiver | Active |
| PFIZER INC | Certificate of waiver | Terminated |
| PFIZER INC | Certificate of waiver | Terminated |
Showing 5 of 10 certificates.
Biomarker capability evidence (9,966)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCB1 | Trial collaborator | Named in trial inclusion criteria |
| ABCC6 | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 9,966 evidence rows.
On Scientist.com
PFIZER INC. is listed as a research supplier in the Scientist.com network.
Service areas
Anacor Pharmaceuticals develop novel small molecule therapeutics derived from their boron chemistry platform.
- Website
- www.anacor.com
Not on this page
Checked, with nothing recorded for this organization: fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, and biomarkers this organization publishes on.
Work with Anacor Pharmaceuticals on Scientist.com
For prices, more details, or to contact Anacor Pharmaceuticals, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.